The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential. [Yahoo! Finance]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Yahoo! Finance
This occurred when its mRNA-based COVID-19 vaccine was one of the first to be granted emergency-use authorization and distributed globally. This opportunity also validated Moderna's mRNA platform's effectiveness and scalability, boosting the company's stock price by more than 1,200% between 2020 and 2022. Another such clinical-stage contender generating growing excitement is Intellia Therapeutics (NTLA), a CRISPR/Cas9-based gene-editing company. Intellia aims to provide one-time, curative treatments for serious genetic diseases. Intellia's stock has fallen 1.9% year-to-date, while the broader market, as tracked by the S&P 500 Index ($SPX), has risen 6%. This Analyst Just Raised His Broadcom Stock Price Target by 70%. Should You Buy AVGO Now? Why Alibaba Stock Looks Like a Screaming Buy After Falling 27% From Its 2025 Highs 2 ETFs Offering Juicy Dividend Yields of 20% or Higher Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive chart
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics (NASDAQ:NTLA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NTLA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics: Critical Safety Updates Are Imminent - Expect Volatility [Seeking Alpha]Seeking Alpha
NTLA
Earnings
- 11/6/25 - Beat
NTLA
Sec Filings
- 12/12/25 - Form 4
- 12/11/25 - Form 144
- 11/12/25 - Form SCHEDULE
- NTLA's page on the SEC website